Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2020

View Archived Issues

CSL begins phase II study of CSL-346 in diabetic kidney disease

Optimization of selective TLR7/TLR8 dual antagonists using a new antagonist competition assay

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Roche opens enrollment in phase III studies of crovalimab for PNH

New phase I/II study evaluates melanoma peptide vaccine with adjuvants

FDA approves Simponi Aria for pJIA and PsA in pediatric patients

Sorrento and ViralClear to explore combination therapy against COVID-19

FDA accepts IND application for phase IIb/III study of mesdopetam in PD-LIDs

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology patent BTK inhibitors

Macrophage migration inhibitory factor inhibitors discovered at Immunophage Biomedical

Alterity Therapeutics identifies compounds that modulate biological metals

Zhejiang Huahai Pharmaceutical, Shanghai Synergy Pharmaceutical Sciences disclose JAK inhibitors

AbbVie, Calico Life Sciences discover PTPN1/2 inhibitors

Enrollment begins in phase I/II study of 4D-310 gene therapy

Stem cells can help stem Klebsiella infection

Phase I study results with ST-617 for oral mucositis lead to phase II planning

Results from JAVELIN Head & Neck 100: avelumab fails in combination with chemoradiation

Overall survival data presented from phase III from SOLAR-1 study of alpelisib plus fulvestrant

Baylx gets IND approval to conduct study of BX-U001 in patients with COVID-19

Survival not improved with vandetanib added to fulvestrant in metastatic ER+ breast cancer

FDA clears IND for phase I studies of TNB-486 in B-cell malignancies

IntraBio's multinational trial of IB-1001 in Niemann-Pick disease type C meets primary endpoint

FDA lifts clinical hold on Solid's phase I/II study of SGT-001 in DMD

FDA issues complete response letter for remestemcel-L in pediatric steroid-refractory acute GvHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...